Related Experiment Video
Updated: Jul 2, 2025
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
12.0K
Semaglutide improves metabolic dysfunction-associated steatohepatitis: A 10-year retrospective study.
Parth Shah1, Megan White1, Alex Sievert2
1Division of Gastroenterology Washington University in Saint Louis Saint Louis Missouri USA.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology
|February 23, 2024
Summary
Semaglutide improved liver enzymes and MASH scores in patients with metabolic dysfunction-associated steatohepatitis (MASH). These benefits were linked to longer treatment duration, not weight loss.
Area of Science:
- Hepatology
- Endocrinology
- Pharmacology
Background:
- Metabolic dysfunction-associated steatohepatitis (MASH) is linked to inflammation, with semaglutide explored for potential benefits.
- Preclinical data suggest MASH improvement with semaglutide may occur independently of weight loss.
Purpose of the Study:
- To evaluate the impact of semaglutide on MASH.
- To determine if MASH improvement is associated with weight loss.
Main Methods:
- Retrospective analysis of 420 diabetic patients on semaglutide for ≥12 months.
- Exclusion of patients with other liver diseases, decompensated cirrhosis, malignancy, or bariatric surgery.
- Primary endpoints: clinically significant improvements in AST/ALT; secondary: MASH scores (NFS, FIB4, APRI).
Main Results:
- Semaglutide treatment (median 22.5 months, 1mg/week for 80%) improved BMI, weight, AST, and ALT.
- Clinically significant improvements in AST/ALT observed in 28%/22% of patients.
- MASH scores significantly improved (p < 0.001); improvements were independent of BMI or weight loss percentage.
Conclusions:
- Semaglutide treatment demonstrated efficacy in improving transaminases and MASH scores.
- Longer treatment duration correlated with better outcomes, independent of weight loss.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187
01:29Chronic Pancreatitis II: Collaborative Care
90
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
90
01:30Acute Pancreatitis II: Clinical Manifestations and Management
124
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
124